Galectin-3: a novel biomarker of glycogen storage disease type III
Glycogen storage disease type III (GSDIII) is a rare genetic disorder leading to abnormal glycogen storage in the liver and skeletal muscle. In this study, we conducted a comparative gene expression analysis of several in vitro and in vivo models and identified galectin-3 as a potential biomarker of the disease. Interestingly, we also observed a significant decrease in galectin-3 expression in mice treated with an AAV gene therapy. Finally, galectin-3 expression was studied in muscle biopsies of GSDIII patients, confirming its increase in patient tissue. Beyond the identification of this novel biomarker, our study offers a new perspective for future therapeutic developments.
Authors
- Louisa Jauze (ORCID: https://orcid.org/0000-0002-9474-6377)
- Quentin Miagoux (ORCID: https://orcid.org/0000-0002-5731-5279)
- Lucile Hoch (ORCID: https://orcid.org/0000-0002-7264-9031)
- Pascal Laforêt (ORCID: https://orcid.org/0000-0002-4489-4718)
- Manon Benabidès
- Giuseppe Ronzitti (ORCID: https://orcid.org/0000-0002-9184-0210)
- Xavier Nissan (ORCID: https://orcid.org/0000-0003-3374-6274)
- Margot Jarrige (ORCID: https://orcid.org/0000-0002-5877-2615)
- Hélène Polvèche (ORCID: https://orcid.org/0000-0002-5601-3498)
- Lucille Rossiaud
- Océane Reiss
Institutions
- Inserm (FR)
- Université Paris-Est Créteil (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Sud Francilien (FR)
- Genethon (France) (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Hôpital Raymond-Poincaré (FR)
- Institut Mondor de Recherche Biomédicale (FR)
- Université d'Évry Val-d'Essonne (FR)
Publication Details
- Journal
- Cell Death Discovery
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1038/s41420-025-02452-6
- Citations
- 1
- Primary Topic
- Galectins and Cancer Biology
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- French Muscular Dystrophy Association
- Fondation Maladies Rares
- Agence Nationale de la Recherche